What was known before {#section11-2054358118783761}
=====================

Patterns of palliative service use and associated outcomes among Canadians on chronic dialysis were previously unknown.

What this adds {#section12-2054358118783761}
==============

In this study, we found very low overall rates of home palliative service use among Ontarians on chronic dialysis. Patients who died while on chronic dialysis used acute inpatient, emergency, and intensive care services. Measures reported in this study can be used as a baseline against which to track future improvements in palliative and end-of-life care provided to chronic dialysis patients.

Introduction {#section13-2054358118783761}
============

Accessible and high-quality palliative care remains a Canadian national priority. Since the recognition of suboptimal palliative care capacity 2 decades ago,^[@bibr1-2054358118783761]^ policy reforms and, ultimately, the Canadian Federal Health Accord of 2003 led to major federal and provincial investments. These were aimed at shifting end-of-life care from acute care hospitals to preferred settings, by enhancing system capacity and improving the coordination of care.^[@bibr2-2054358118783761],[@bibr3-2054358118783761]^ In Ontario, efforts to bolster the palliative care system have largely focused on cancer patients, who have historically constituted 85% of palliative care referrals.^[@bibr4-2054358118783761]^ The establishment of Cancer Care Ontario in 1997 led to a formal End-of-Life Care Strategy and the creation of various structures and collaborations that have translated into better outcomes and less resource use.^[@bibr4-2054358118783761]^ In 2011, the Declaration of Partnership and Commitment to Action was developed and articulated a shared vision of palliative care in Ontario that was disease agnostic.^[@bibr5-2054358118783761]^

End-stage kidney disease (ESKD) is a debilitating condition with limited life expectancy and symptom burden that rivals that of many cancers.^[@bibr6-2054358118783761]^ Recognizing the progressive nature of kidney disease, and the high burden of concomitant frailty and comorbidity in the ESKD population, all aspects of palliative care planning and delivery have become a focus of attention in the kidney community.

The Ontario Renal Network (ORN) oversees the funding and quality of kidney care services for patients in Ontario with chronic kidney disease (CKD). Over 11 000 Ontario residents receive some form of dialysis care. Through engagement of patients and other stakeholders, the ORN has developed a 5-year strategic plan, published in the 2015-2019 Ontario Renal Plan (ORP), to improve access to palliative care services; enhance kidney health-system integration with primary care, home, and community services; and improve provider competency in facilitating patient education and shared decision-making.^[@bibr7-2054358118783761]^ To guide quality improvement initiatives and obtain baseline measures against which to track progress, we undertook a current-state analysis of home palliative care (hPC) service use and outcomes in Ontario's dialysis population.

Methods {#section14-2054358118783761}
=======

Study Design and Setting {#section15-2054358118783761}
------------------------

We conducted a retrospective descriptive cohort study using linked healthcare databases held at the Institute for Clinical Evaluative Sciences (ICES) in Ontario. Ontario residents receive universal healthcare with most encounters captured in administrative data. Funded palliative services range from home care (nurse, physician, personal support worker, or multidisciplinary teams), palliative care clinics, hospice care facilities, and inpatient palliative consultative services. Given the central role of home services in Ontario's palliative care strategies, we restricted our analyses to administrative codes representing hPC services. This study was approved by the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). Manuscript preparation adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([Appendix A](#table3-2054358118783761){ref-type="table"}).^[@bibr8-2054358118783761]^

We used an integrated knowledge translation approach to develop our research protocol and interpret our findings with the Ontario Renal Network Palliative Care Priority Panel---the advisory group that oversees the provincial renal palliative care strategy and includes palliative care physicians, the full spectrum of healthcare provider stakeholders, administrators, patients, and families.

Data Sources {#section16-2054358118783761}
------------

We ascertained baseline characteristics and outcomes using a variety of linked databases (details below and [Appendix B](#table4-2054358118783761){ref-type="table"}). We obtained death date and other vital statistics from the Registered Persons Database. We identified individuals on chronic dialysis using the Canadian Organ Replacement Register (CORR) and the Ontario Renal Reporting System (ORRS). We captured nurse and physician hPC codes in the Ontario Health Insurance Plan (OHIP), Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD), National Ambulatory Care Reporting System (NACRS), Home Care Database (HCD), Continuing Care Reporting System (CCRS), Resident Assessment Instrument (RAI)--Contact Assessment (CA), and RAI--Home Care (HC). All databases were linked using unique encoded identifiers and analyzed at ICES.

Population {#section17-2054358118783761}
----------

We identified chronic dialysis patients who died between January 1, 2010, and December 31, 2014, in CORR and ORRS, and used their death date as the index date. We looked back 365 days from this index date to determine their trajectory of care in the last year of life. Patients who had received a kidney transplant required a minimum survival on dialysis of at least one year after transplant failure before they could enter the cohort. We reported outcomes separately for patients who received and did not receive hPC services in the last year of life. We also identified a subgroup of patients who electively discontinued dialysis within 30 days of death ([Figure 1](#fig1-2054358118783761){ref-type="fig"}). Home palliative care service use was defined as receiving at least one administrative code from OHIP, HCD, RAI-CA, or RAI-HC at any time in the last year of life ([Appendix C](#table5-2054358118783761){ref-type="table"}). We counted the number of days that a patient had received at least one palliative care code to define a palliative visit (ie, multiple codes on the same day were counted as a single encounter). We did not count hospital or clinic-based palliative care visits in the main analysis. We ascertained home deaths using OHIP codes.

![Cohort flow diagram.\
*Note.* CORR = Canadian Organ Replacement Register; ORRS = Ontario Renal Reporting System.](10.1177_2054358118783761-fig1){#fig1-2054358118783761}

Variables {#section18-2054358118783761}
---------

We ascertained demographic information at the time of death. We looked back to 1981 in CORR (inception) to identify complete dialysis history. We defined dialysis discontinuation using ORRS codes for patients marked as having withdrawn from dialysis, counting only those who died within 30 days of dialysis discontinuation to limit misclassification where dialysis was stopped due to kidney recovery.

We captured comorbidities within 2 years of death using OHIP, CIHI-DAD, and NACRS. We used the Johns Hopkins Adjusted Clinical Group (ACG) system to score comorbidity.^[@bibr9-2054358118783761]^ The ACG estimates an individual's expected service use. The International Classification of Diseases, Ninth Revision (ICD-9) and The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes are categorized into 32 groups, called Ambulatory Diagnostic Groups (ADGs), then further reduced to 12 "Collapsed ADGs" or Collapsed Aggregated Diagnosis Groups (CADGs).^[@bibr10-2054358118783761]^

A panel of content experts prioritized candidate outcomes based on importance and feasibility, given available data. These outcomes were (1) emergency department (ED) visits, (2) intensive care unit (ICU) visits, (3) time to death (starting at dialysis initiation), and (4) place of death. Place of death was coded as ICU, acute care hospital, or ED (counted together because most patients that died in hospital had a corresponding ED visit), long-term care, complex continuing care, home, or unattended death/unknown. If a patient had an admission to ICU, hospital, and Emergency Room (ER), they were considered to have had a hospital death with an ICU stay. We coded patients as having died at home only if they had an associated OHIP code for pronouncement of death at home.

Statistical Analyses {#section19-2054358118783761}
--------------------

We reported baseline characteristics as frequencies and proportions, medians and interquartile ranges (IQRs) as appropriate. We compared patient characteristics using standardized differences across categories of hPC service use and considered a difference of ⩾10% significant. We reported outcomes as counts and proportions, and medians with corresponding first/third quartiles for continuous variables. We used SAS software, version 9.4 (SAS Institute Inc, Cary, North Carolina) for statistical analyses.

Results {#section20-2054358118783761}
=======

Patient Characteristics {#section21-2054358118783761}
-----------------------

We identified 9611 chronic dialysis patients ([Figure 1](#fig1-2054358118783761){ref-type="fig"}) who died between 2010 and 2014. Sociodemographic characteristics, dialysis modalities, and comorbidities did not differ by year of death (data not shown). The characteristics of the entire cohort are presented in [Table 1](#table1-2054358118783761){ref-type="table"}. At the time of death, the median age in the overall cohort was 75.0 years, 40.6% were women, and 11.5% resided in rural locations. Comorbid conditions included high rates of diabetes (65.0%), ischemic heart disease (55.3%), congestive heart failure (55.5%), and dementia (29.6%). Patients had received dialysis for a median of 3.0 years prior to death, and 4.0% had a history of transplant, with a median time from transplant to reinitiation of chronic dialysis being 13.0 years (IQR: 13). A total of 912 (19.9%) discontinued dialysis in the last 30 days of life.

###### 

Patient Characteristics at Time of Death in Overall 2010 to 2014 Cohort, As Well As Stratified by Patients Receiving/Not Receiving at Least One Home Care Palliative Care Visit in the Last Year of Life With Associate Standardized Differences.

![](10.1177_2054358118783761-table1)

  Characteristic                                                                             Total                                                                At least one home care palliative service in last 365 days of life   No home care palliative service in last 365 days of life   Standardized difference^[a](#table-fn2-2054358118783761){ref-type="table-fn"}^
  ------------------------------------------------------------------------------------------ -------------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------
  Total chronic dialysis patients                                                            9611 (100.0)                                                         1258 (13.1)                                                          8353 (87.0)                                                ---
  Age                                                                                                                                                                                                                                                                                             
   Median (25th-75th percentiles)                                                            75.0 (66.0-82.0)                                                     77.0 (68.0-83.0)                                                     75.0 (65.0-82.0)                                           14.3
  Women                                                                                      3898 (40.6)                                                          503 (40.0)                                                           3395 (40.6)                                                1.3
  Rural residence^[b](#table-fn3-2054358118783761){ref-type="table-fn"}^                     1101 (11.5)                                                          182 (14.5)                                                           919 (11.0)                                                 10.4
  Income quintiles^[c](#table-fn4-2054358118783761){ref-type="table-fn"}^                                                                                                                                                                                                                         
   1 (lowest)                                                                                2369 (24.7)                                                          268 (21.3)                                                           2101 (25.2)                                                9.1
   2                                                                                         2137 (22.2)                                                          238 (18.9)                                                           1899 (22.7)                                                9.4
   3                                                                                         1823 (19.0)                                                          247 (19.6)                                                           1576 (18.9)                                                2.0
   4                                                                                         1771 (18.4)                                                          255 (20.3)                                                           1516 (18.2)                                                5.4
   5 (highest)                                                                               1511 (15.7)                                                          250 (19.9)                                                           1261 (15.1)                                                12.6
  Johns Hopkins Expanded Diagnosis Clusters                                                                                                                                                                                                                                                       
   Cerebrovascular disease                                                                   2538 (26.4)                                                          293 (23.3)                                                           2245 (26.9)                                                8.3
   Congestive heart failure                                                                  5331 (55.5)                                                          637 (50.6)                                                           4694 (56.2)                                                11.2
   Dementia & delirium                                                                       2848 (29.6)                                                          360 (28.6)                                                           2488 (29.8)                                                2.6
   Ischemic heart disease                                                                    5319 (55.3)                                                          620 (49.3)                                                           4699 (56.3)                                                14.0
   High impact malignant neoplasms^[d](#table-fn5-2054358118783761){ref-type="table-fn"}^    1337 (13.9)                                                          500 (39.8)                                                           837 (10.0)                                                 73.2
   Low impact malignant neoplasms^[d](#table-fn5-2054358118783761){ref-type="table-fn"}^     1284 (13.4)                                                          357 (28.4)                                                           927 (11.1)                                                 44.5
   Peripheral vascular disease                                                               2394 (24.9)                                                          244 (19.4)                                                           2150 (25.7)                                                15.2
   Diabetes                                                                                  6242 (65.0)                                                          721 (57.3)                                                           5521 (66.1)                                                18.1
  John Hopkins Adjusted Clinical Group comorbidity score                                                                                                                                                                                                                                          
   Median (25th-75th percentiles)                                                            14.0 (12.0-16.0)                                                     15.0 (12.0-17.0)                                                     14.0 (11.0-16.0)                                           18.6
  Comorbidities 2 years from death^[e](#table-fn6-2054358118783761){ref-type="table-fn"}^:                                                                                                                                                                                                        
   Immobility^[f](#table-fn7-2054358118783761){ref-type="table-fn"}^                         75 (0.8)                                                             12 (1.0)                                                             63 (0.8)                                                   2.2
   Lower leg amputation                                                                      694 (7.2)                                                            54 (4.3)                                                             640 (7.7)                                                  14.2
   Myocardial infarction                                                                     2239 (23.3)                                                          191 (15.2)                                                           2048 (24.5)                                                23.6
   Gastrointestinal hemorrhage                                                               1000 (10.4)                                                          127 (10.1)                                                           873 (10.5)                                                 1.2
  Time on chronic dialysis (years)                                                                                                                                                                                                                                                                
   Median (25th-75th percentiles)                                                            3.0 (1.0-6.0)                                                        2.0 (1.0-5.0)                                                        3.0 (1.0-6.0)                                              13.6
  Cause of end-stage renal disease                                                                                                                                                                                                                                                                
   Diabetes                                                                                  1581 (16.5)                                                          119 (9.5)                                                            1462 (17.5)                                                23.7
   Vascular disease                                                                          981 (10.2)                                                           131 (10.4)                                                           850 (10.2)                                                 0.8
   Glomerulonephritis                                                                        425 (4.4)                                                            48 (3.8)                                                             377 (4.5)                                                  3.5
   Other                                                                                     266 (2.8)                                                            43 (3.4)                                                             223 (2.7)                                                  4.4
   Polycystic kidney disease                                                                 120 (1.3)                                                            15 (1.2)                                                             105 (1.3)                                                  0.3
   Obstruction                                                                               95 (1.0)                                                             11 (1.6)                                                             84 (1.0)                                                   1.4
   Missing                                                                                   6113 (63.6)                                                          886 (70.4)                                                           5227 (62.6)                                                16.7
  Initial dialysis modality                                                                                                                                                                                                                                                                       
   In-centre hemodialysis                                                                    7151 (74.4)                                                          949 (75.4)                                                           6202 (74.3)                                                2.7
   Peritoneal dialysis                                                                       ⩾806 (⩾8.4)^[g](#table-fn8-2054358118783761){ref-type="table-fn"}^   ⩾77 (⩾6.1)^[g](#table-fn8-2054358118783761){ref-type="table-fn"}^    729 (8.7)                                                  10.0^[h](#table-fn9-2054358118783761){ref-type="table-fn"}^
   Home hemodialysis                                                                         ⩽17 (⩽0.2)^[g](#table-fn8-2054358118783761){ref-type="table-fn"}^    ⩽5 (⩽0.4)^[g](#table-fn8-2054358118783761){ref-type="table-fn"}^     12 (0.1)                                                   0.5^[h](#table-fn9-2054358118783761){ref-type="table-fn"}^
   Missing                                                                                   1637 (17.0)                                                          227 (18.0)                                                           1410 (16.9)                                                3.1
  Final dialysis modality                                                                                                                                                                                                                                                                         
   In-centre hemodialysis                                                                    7597 (79.0)                                                          983 (78.1)                                                           6614 (79.2)                                                2.5
   Peritoneal dialysis                                                                       477 (5.0)                                                            81 (6.4)                                                             396 (4.7)                                                  7.4
   Home hemodialysis                                                                         49 (0.5)                                                             10 (0.8)                                                             39 (0.5)                                                   4.1
   Missing                                                                                   1344 (14.0)                                                          170 (13.5)                                                           1174 (14.1)                                                1.6
  Kidney transplant recipient                                                                381 (4.0)                                                            47 (3.7)                                                             334 (4.0)                                                  1.4

*Note.* EDCs = Johns Hopkins Extended Diagnosis Clusters^TM^; CIHI-DAD = Canadian Institute for Health Information Discharge Abstract Database; ACG = Adjusted Clinical Group®; ESRD = end-stage renal disease; LTC = long-term care.

Standardized differences (SD) are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled SD; a value greater than 10% is interpreted as a meaningful difference between groups. Some cell values were suppressed for the purposes of privacy and confidentiality.

Rural was defined as population \< 10 000.

Income was categorized into fifths of average neighborhood income on death date. Income Quintile category 3 includes the missing values.

Malignant neoplasm categories were defined using Johns Hopkins Expanded Diagnosis Clusters (EDC), which are based on proprietary ICD codes.

Comorbidities were assessed by administrative database codes or by EDC in the previous 2 years from death

Immobility was defined using ICD-10 codes in CIHI-DAD: "R263," "R2681," "Z740."

Number have been altered to suppress small cells.

Standardized difference has been changed to accommodate suppressed cells.

Home Palliative Care Service Use in the Final Year of Life {#section22-2054358118783761}
----------------------------------------------------------

Among the 9611 chronic dialysis patients who died during the study period, 1258 (13.1%) received at least 1 hPC service in the last year of life. Compared with those who received no hPC, hPC recipients had fewer comorbidities, with the exception of concurrent malignancy ([Tables 1](#table1-2054358118783761){ref-type="table"} and [2](#table2-2054358118783761){ref-type="table"}). Among the 7699 patients who did not discontinue dialysis, 742 (9.6%) received hPC services in the last year of life. In contrast, 516 (27.0%) of those who discontinued dialysis received hPC services.

###### 

Comparison of Home Palliative Care Service Measures in the Last Year of Life and Outcomes Among Ontario Residents Who Died on or Discontinued Chronic Dialysis.

![](10.1177_2054358118783761-table2)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       Overall cohort   Overall cohort by palliative care status\   Patients who died while receiving dialysis\   Patients who discontinued dialysis within the last 30 days of life\                                     
                                                                                                        (n = 9611)                                  (n = 7699)                                    (n = 1912)                                                                                              
  ------------------------------------------------------------------------------------ ---------------- ------------------------------------------- --------------------------------------------- --------------------------------------------------------------------- ---------------- ---------------- ----------------
  Number of patients                                                                   9611             8353                                        1258                                          6957                                                                  742              1396             516

  ED visits                                                                                                                                                                                                                                                                                               

   In last 14 days                                                                     4239 (44.1)      3776 (45.2)                                 463 (36.8)                                    3329 (47.9)                                                           317 (42.7)       447 (32.0)       146 (28.3)

   In last 30 days                                                                     5771 (60.0)      5084 (60.9)                                 687 (54.6)                                    4326 (62.2)                                                           423 (57.0)       758 (54.3)       264 (51.2)

  ICU admissions                                                                                                                                                                                                                                                                                          

   In last 14 days                                                                     3503 (36.4)      3349 (40.1)                                 154 (12.2)                                    2957 (42.5)                                                           105 (14.2)       392 (28.1)       49 (9.5)

   In last 30 days                                                                     3687 (38.4)      3500 (41.9)                                 187 (14.9)                                    3075 (44.2)                                                           123 (16.6)       425 (30.4)       64 (12.4)

  Survival time, years                                                                                                                                                                                                                                                                                    

   Median (25th-75th percentiles)                                                      2.7 (0.9, 5.6)   2.8 (0.9, 5.8)                              2.0 (0.8, 4.7)                                2.8 (1.0, 5.8)                                                        1.9 (0.8, 4.4)   2.9 (0.8, 5.7)   2.4 (0.8, 5.2)

  Location of death                                                                                                                                                                                                                                                                                       

   ICU                                                                                 3256 (33.9)      3154 (37.8)                                 102 (8.1)                                     2826 (40.6)                                                           78 (10.5)        328 (23.5)       24 (4.7)

   Acute care hospital or ED^[a](#table-fn11-2054358118783761){ref-type="table-fn"}^   3484 (36.3)      3094 (37.0)                                 390 (31.0)                                    2503 (36.0)                                                           272 (36.7)       591 (42.3)       118 (22.9)

   LTC                                                                                 592 (6.2)        567 (6.8)                                   25 (2.0)                                      359 (5.2)                                                             15 (2.0)         208 (14.9)       10 (1.9)

   CCC                                                                                 750 (7.8)        640 (7.7)                                   110 (8.7)                                     427 (6.1)                                                             57 (7.7)         213 (15.3)       53 (10.3)

   Home                                                                                328 (3.4)        113 (1.4)                                   215 (17.1)                                    101 (1.5)                                                             101 (13.6)       12 (0.9)         114 (22.1)

   Other/unknown                                                                       1201 (12.5)      785 (9.4)                                   416 (33.1)                                    741 (10.7)                                                            219 (29.5)       44 (3.2)         197 (38.2)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* ED = emergency department; ICU = intensive care unit; LTC = long-term care; CCC = complex continuing care. All values expressed as n (%) unless otherwise specified. Survival time is defined as the number of years between the first-ever ESKD service date and death date; presented values are median (25th, 75th percentile).

Acute care hospital and ED visits were combined to avoid small cells, and for the purposes of ensuring privacy and confidentiality.

Of those who received hPC services, only 382 (30.3%) had one or more visits in the period 31 to 365 days prior to death, while the majority (n = 1036, 82.4%) had visit(s) only in the last 30 days of life. Among those who received an hPC visit, most received a single such visit (n = 685, 54.4% of those receiving hPC) often within the last 30 days of life (n = 876, 69.6%). A total of 564 (44.8%) of these patients received their first visit in the 7 days prior to death.

ED Visits {#section23-2054358118783761}
---------

The proportion of all dialysis patients who died and had ⩾1 ED visit in the last 14 and 30 days of life was 44.1% and 60.0%, respectively ([Table 2](#table2-2054358118783761){ref-type="table"}). Patients had fewer ED visits in the last year of life if they had hPC services.

ICU Admissions {#section24-2054358118783761}
--------------

Patients who received hPC services had fewer admissions to ICU in the last days of life (12.2 and 14.9% within 14 and 30 days, respectively), compared with patients who did not receive hPC (40.1 and 41.9% within 14 and 30 days, respectively).

Time to Death {#section25-2054358118783761}
-------------

The median (IQR) time on dialysis before death was 2.7 (4.7) years for all patients (n = 9611) ([Table 2](#table2-2054358118783761){ref-type="table"}). Patients who had received hPC services had a marginally shorter time on dialysis (median: 2.0 years; IQR: 3.9) than those who did not have any palliative care visits (median: 2.8 years; IQR: 4.9). Similar results were seen for those who discontinued dialysis. The median time to death from discontinuation of dialysis was 4 days (IQR: 6).

Location of Death {#section26-2054358118783761}
-----------------

In the overall cohort, 70.2% of patients died in the ED, acute care hospital, or ICU. Patients who received one or more hPC visits (vs none) were more likely to die at home (17.1 vs 1.4%). Patients who received hPC in the last year had a higher rate of deaths in unclassified locations (33.1%) compared with those who received no hPC (9.4%).

Sensitivity Analyses {#section27-2054358118783761}
--------------------

We repeated the main analysis after restricting the observation window for hPC services to the final 30 days of life. All results were qualitatively similar in direction and magnitude as in the main analysis in which we captured hPC service use in the last 365 days of life. In addition, we analyzed the data using inpatient palliative care service visits (DAD and OHIP). Results were similar for most comparisons. The details of these analyses are available upon request.

Subgroup Analysis {#section28-2054358118783761}
-----------------

Among the 1912 patients who discontinued dialysis, 516 (27.0%) received hPC in the final 365 days of life. Compared with those who had no hPC, those who received hPC had similar rates of ED visits, but lower rates of ICU admission (30.4 vs 12.4%) and fewer deaths in ICU (23.5 vs 4.7%) or acute care hospital/ED (42.3 vs 22.9).

Discussion {#section29-2054358118783761}
==========

We report a current-state analysis of hPC use among Ontario residents maintained on chronic dialysis. We found that hPC services are infrequently used in this population and that, in most cases, used only within the last days of life.

Our findings suggest that at present, there is infrequent and late collaboration with home-based palliative care teams. We found, much like other studies,^[@bibr11-2054358118783761][@bibr12-2054358118783761][@bibr13-2054358118783761]-[@bibr14-2054358118783761]^ that palliative services were mostly used in end-of-life situations. Even when death is anticipated, patients most often do not appear to receive palliative care. In our cohort, only 27% of patients who discontinued dialysis received home palliative services in the last year of life. In their series, Couchoud et al found that among patients who discontinued dialysis while in hospital, 90% were not admitted to designated palliative care beds.^[@bibr15-2054358118783761]^ While various patient, hospital, and system-level barriers may limit patients' access to palliative services, provider attitudes and practices are likely major determinants of palliative care use. In a questionnaire-based study of European nephrologists, only 10% reported involving palliative care services when they started discussions around dialysis discontinuation.^[@bibr14-2054358118783761]^ In a recent survey of Ontario renal providers (nurses, physicians and social workers), the provincial mean score on a subscale measuring providers' propensity to engage community palliative services was only 2.5 out of 5.0, suggesting room for improvement (unpublished data, Ontario Renal Network).

A large proportion of patients in our cohort had ED and ICU visits during their final days of life. This is consistent with the high rate of cardiovascular and infection-related death in the dialysis-treated population.^[@bibr16-2054358118783761]^ Patients who received hPC had fewer ED and ICU visits compared with those who did not. However, in this descriptive study, we did not adjust for confounders that might have accounted for these differences. Interestingly, patients who received hPC had a higher rate of high-impact neoplasia compared with those who did not (39.8 vs 10.0%), suggesting that they may have accessed hPC through the cancer care system.

Developing disease-agnostic palliative care services is a priority in Ontario. These services are intended to extend beyond end-of-life care and provide multidisciplinary symptom and existential support to individuals with life-limiting, progressive, and burdensome disease. When optimally used, palliative care is introduced early in the disease trajectory and is provided in conjunction with disease modifying treatments.^[@bibr17-2054358118783761][@bibr18-2054358118783761]-[@bibr19-2054358118783761]^ As the disease progresses along the trajectory, the focus of care shifts, gradually, from disease-modification to symptom management and focuses largely on the individual patient's experience. ESKD is well recognized as a serious and life-limiting illness with a high symptom burden. Treatments often centre around dialysis care, with until recently, little focus on symptom management or the patient experience. We observed that, in Ontario, palliative care was not being used in this way, with most hPC recipients having only 1 hPC visit. This finding suggests it is unlikely patients have sufficient time to establish a trusting relationship with the palliative care team with, likely, a higher reliance on care provided in the acute care setting. We also found a high rate of deaths occurring in hospital, often in association with an ICU stay. Although it is not possible from these data to tease out those deaths that were unexpected from those potentially anticipated, it is likely that a substantial proportion of these patients had predicable chronic disease progression and may have benefitted from hPC services at an earlier stage of their disease trajectory.

Our study has recognized limitations. Our findings may not be generalizable outside of Ontario. We used administrative data, which did not allow for analysis of patient and family experience, quality and appropriateness of care, and the specific types of services provided. We did not analyze referral sources (eg, primary care versus nephrology). Death location was unconfirmed in up to 38% of patients, as it could only be ascertained through an OHIP claim for pronouncement of death at home, or if the death occurred in an institution. However, it is very likely that most undocumented deaths occurred in the home setting; hence, home deaths likely occurred in 16% for the overall cohort and 50% for patients who had one or more hPC encounter, which is in keeping with patients' preferences as captured in surveys.^[@bibr20-2054358118783761]^

These limitations notwithstanding, our findings identify opportunities for improvement and provide baseline measures for gauging the success of future efforts. In a comprehensive provincial strategy, we hope to improve patients' access to and experience of care by introducing interventions including formalized goals of care assessments, patient and provider education, standardized care pathways, and team-based approaches and by improving collaboration with primary care.^[@bibr21-2054358118783761]^ Developing these interventions in partnership with patients and families, partner agencies,^[@bibr5-2054358118783761]^ and the primary care community will be critical to the success of the provincial renal palliative care strategy.
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STROBE Criteria.
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                                                                                                          Item No.                                             Recommendation                                                                                                                                                                                                   Reported
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Title and abstract                                                                                      1                                                    \(a\) Indicate the study's design with a commonly used term in the title or the abstract                                                                                                                         Title Page
  \(b\) Provide in the abstract an informative and balanced summary of what was done and what was found   Abstract                                                                                                                                                                                                                                                              
  Introduction                                                                                                                                                                                                                                                                                                                                                                  
   Background/rationale                                                                                   2                                                    Explain the scientific background and rationale for the investigation being reported                                                                                                                             Introduction
   Objectives                                                                                             3                                                    State specific objectives, including any prespecified hypotheses                                                                                                                                                 Introduction (last paragraph)
  Methods                                                                                                                                                                                                                                                                                                                                                                       
   Study design                                                                                           4                                                    Present key elements of study design early in the paper                                                                                                                                                          Methods
   Setting                                                                                                5                                                    Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection                                                                                  Methods
   Participants                                                                                           6                                                    \(a\) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up                                                                                     Methods
  \(b\) For matched studies, give matching criteria and number of exposed and unexposed                   NA                                                                                                                                                                                                                                                                    
   Variables                                                                                              7                                                    Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable                                                                         Methods
   Data sources/ Measurement                                                                              8                                                    For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group                             Methods
   Bias                                                                                                   9                                                    Describe any efforts to address potential sources of bias                                                                                                                                                        NA
   Study size                                                                                             10                                                   Explain how the study size was arrived at                                                                                                                                                                        Methods
   Quantitative variables                                                                                 11                                                   Explain how quantitative variables were handled in the anayses. If applicable, describe which groupings were chosen and why                                                                                      Methods
   Statistical methods                                                                                    12                                                   \(a\) Describe all statistical methods, including those used to control for confounding                                                                                                                          Methods
  \(b\) Describe any methods used to examine subgroups and interactions                                   Methods                                                                                                                                                                                                                                                               
  \(c\) Explain how missing data were addressed                                                                                                                                                                                                                                                                                                                                 
  \(d\) If applicable, explain how loss to follow-up was addressed                                        NA                                                                                                                                                                                                                                                                    
  \(e\) Describe any sensitivity analyses                                                                 NA                                                                                                                                                                                                                                                                    
  Results                                                                                                                                                                                                                                                                                                                                                                       
   Participants                                                                                           13                                                   \(a\) Report numbers of individuals at each stage of study---eg, numbers potentially eligible, examined for eligibilty, confirmed eligible, included in the study, completing follow-up, and analysed            [Figure 1](#fig1-2054358118783761){ref-type="fig"} and Results
  \(b\) Give reasons for nonparticipation at each stage                                                   [Figure 1](#fig1-2054358118783761){ref-type="fig"}                                                                                                                                                                                                                    
  \(c\) Consider use of a flow diagram                                                                    [Figure 1](#fig1-2054358118783761){ref-type="fig"}                                                                                                                                                                                                                    
   Descriptive data                                                                                       14                                                   \(a\) Give charchteristics of study participants (eg, demographic, clinical, social) and information on exposures and potential confounders                                                                      Results (Patient Characteristis)
  \(b\) Indicate number of participants with missin data for each variable of interest                    NA                                                                                                                                                                                                                                                                    
  \(c\) Summarize follow-up time (eg, average and total amount)                                           NA                                                                                                                                                                                                                                                                    
   Outcome data                                                                                           15                                                   Report numbers of outcome events or summary measures over time                                                                                                                                                   Results and [Table 1](#table1-2054358118783761){ref-type="table"}
   Main results                                                                                           16                                                   \(a\) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   Results and [Table 1](#table1-2054358118783761){ref-type="table"}
                                                                                                                                                               \(b\) Report category boundaries when continuous variables were categorized                                                                                                                                      Results and [Table 1](#table1-2054358118783761){ref-type="table"}
                                                                                                                                                               \(c\) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period                                                                                               NA
   Other analyses                                                                                         17                                                   Report other analyses done---eg,analyses of subgroups and interactions, and sensitivity analyses                                                                                                                 Results and [Table 1](#table1-2054358118783761){ref-type="table"}
  Discussion                                                                                                                                                                                                                                                                                                                                                                    
   Key results                                                                                            18                                                   Summarize key results with reference to study objectives                                                                                                                                                         Discussion
   Limitations                                                                                            19                                                   Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuus both direction and magnitude of any potential bias                                                       Discussion
   Interpretation                                                                                         20                                                   Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                       Discussion
   Generalizability                                                                                       21                                                   Discuss the gerneralisability (external validity) of the study results                                                                                                                                           Discussion
  Other Information                                                                                                                                                                                                                                                                                                                                                             
   Funding                                                                                                22                                                   Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based                                                    Funding

*Note*. STROBE = Strengthening the Reporting of Observational Studies in Epidemiology.
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Description of Databases.

![](10.1177_2054358118783761-table4)

  Type of health services    Database                                                                           Description
  -------------------------- ---------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kidney care                                                                                                   
  Chronic dialysis           Canadian Organ Replacement Register                                                Registry tracking the long-term trends of vital organ transplantation, donations, and dialysis activities.
                             Ontario Renal Reporting System                                                     Database of predialysis, acute dialysis, and chronic dialysis patients in Ontario.
  Acute care                                                                                                    
   Hospital inpatient        Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD)   Patient-level administrative, clinical, and demographic data on hospital discharges from all acute facilities in Ontario
   Emergency department      National Ambulatory Care Reporting System (NACRS)                                  Patient demographics and clinical, administrative, and service-specific data related to emergency department visits
   Physician billings        Ontario Health Insurance Plan (OHIP) Claims Database                               Claims data paid for by the Ontario Health Insurance Plan for approximately 98% of physicians in Ontario who claim under OHIP.
  Continuing care                                                                                               
   Long-term care            Continuing Care Reporting System (CCRS)                                            The CCRS is a database of clinical and demographic information on residents receiving facility based long-term care in Ontario. Contains information on over 600 publicly funded residential care homes with 24-hour nursing care
   Complex continuing care   CCRS                                                                               The CCRS also provides data on hospitalized patients who are deemed to be in a nonacute, alternate level of care, receiving continuing care services.
   Home care                 Home Care Database (HCD)                                                           Data from the Ontario Association of Community Care Access Centres, responsible for providing publicly funded home care. Client-level data for all of those receiving home care services from these facilities.
                             Resident Assessment Instrument (RAI)--Home Care (HC)                               Person-centered assessment system used in home and community-based settings typically among those receiving formal care of supportive services. Dataset captures an individual's functioning and quality of life
                             RAI-Contact Assessment (CA)                                                        A short screening assessment completed at the time of intake into home care services.

###### 

Palliative Care Codes by Administrative Database.
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  Type                                                                                                           Database                                                                                                                                        Code
  -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Acute care services                                                                                            CIHI-DAD                                                                                                                                        PATSERV = 58, Main patient service, palliative care
  OHIP                                                                                                           C945, Special palliative care consult hospital inpatient                                                                                        
  C882, Terminal care in-hospital general practitioner/family practitioner                                                                                                                                                                                       
  C982, Palliative care                                                                                                                                                                                                                                          
  K023, Palliative care support individual care 1/2 h or major part                                                                                                                                                                                              
  Home care services                                                                                             RAI-CA                                                                                                                                          B2c = 1, Referral to initiate or continue palliative services = Yes
  B4 = 12, Expected residential/living status during service provision = Hospice facility/palliative care unit                                                                                                                                                   
  RAI-HC                                                                                                         P2S = 1 or 2, Special Treatments, Therapies, Programs---Hospice Care= Scheduled, full adherence as prescribed OR Scheduled, partial adherence   
  CC3f = 1, Understanding of Goals of Care---Palliative Care = Yes                                                                                                                                                                                               
  OHIP                                                                                                           B966, Travel Premium---Palliative Care Home Visit                                                                                               
  B998, Special visit palliative care home, days or evenings                                                                                                                                                                                                     
  C997, Special visit palliative care home, days or evenings (starting Oct 2009)                                                                                                                                                                                 
  G511, Telephone management of palliative care at home                                                                                                                                                                                                          
  HCD: Clients                                                                                                   SRC_admission = 95, Service Care goals at time of submission for open admission= End of Life (In-Home)                                          
  Service_RPC = 95, Service Recipient Code associated with the care delivery event = End of Life (In-Home)                                                                                                                                                       
  SRC_discharge = 95, Service Care goals (service receipt code) at time of discharge = End of Life (In-Home)                                                                                                                                                     

*Note.* CIHI-DAD = Canadian Institute for Health Information Discharge Abstract Database; OHIP = Ontario Health Insurance Plan; RAI-CA = Resident Assessment Instrument--Contact Assessment; RAI-HC = Resident Assessment Instrument--Home Care; HCD = Home Care Database.
